Expanded access in the Netherlands: prescribing unregistered medicine 39 REFERENCES 1. Darrow JJ, Avorn J, Kesselheim AS. FDA Approval and Regulation of Pharmaceuticals, 19832018. JAMA. 2020;323(2):164-164. doi:10.1001/ jama.2019.20288 2. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012 3. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. Hamel MB, ed. N Engl J Med. 2015;372(3):279-286. doi:10.1056/ NEJMhle1409465 4. Caplan AL, Bateman-House A. Should patients in need be given access to experimental drugs? Expert Opin Pharmacother. 2015;16(9):12751279. doi:10.1517/14656566.2015.1046837 5. Clark LT, Watkins L, Piña IL, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Curr Probl Cardiol. 2019;44(5):148-172. doi:10.1016/j.cpcardiol.2018.11.002 6. Willis A, Isaacs T, Khunti K. Improving diversity in research and trial participation: the challenges of language. Lancet Public Health. 2021;6(7):e445-e446. doi:10.1016/S24682667(21)00100-6 7. Sabin JA. Tackling Implicit Bias in Health Care. N Engl J Med. 2022;387(2):105-107. doi:10.1056/ NEJMp2201180 8. Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA’s Expanded Access Program for Investigational Drugs. Ther Innov Regul Sci. 2017;51(2):177-179. doi:10.1177/2168479017694850 9. Young FE, Norris JA, Levitt JA, Nightingale SL. The FDA’s New Procedures for the Use of Investigational Drugs in Treatment. JAMA J Am Med Assoc. 1988;259(15):2267-2270. doi:10.1001/jama.1988.03720150043034 10. Rosenblatt M, Kuhlik B, Nightingale SL. FDA Expanded Access Programs for Experimental Medicines. JAMA. 2015;314(12):1296-1296. doi:10.1001/jama.2015.9728 11. Nightingale SL. FDA Expanded Access Programs for Experimental Medicines. JAMA. 2015;314(12):1296. doi:10.1001/ jama.2015.9725 12. Sarpatwari A, Darrow JJ, Kesselheim AS, Lurie P, Chan-Tack KM, Woodcock J. Expanded access to investigational drugs. N Engl J Med. 2015;372(15):1473-1473. doi:10.1056/ NEJMc1501823 13. Borysowski J, Saxena A, Bateman-House A, et al. Expanded access: growing importance to public health. J Epidemiol Community Health. 2018;72(7):557-558. doi:10.1136/jech-2017210409 14. Mackey TK, Schoenfeld VJ. Going “Social” to Access Experimental and Potentially LifeSaving Treatment: An Assessment of the Policy and Online Patient Advocacy Environment for Expanded Access. Vol 14.; 2016:17. doi:10.1186/ s12916-016-0568-8 15. Reddy NK, Subbiah V. Right to Try, expanded access use, Project Facilitate, and clinical trial reform. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(9):1083-1086. doi:10.1016/j. annonc.2021.06.016 16. Scepura B, Chan M, Kim T, Boehmer J, Goldberg KB, Pazdur R. Oncology Expanded Access and FDA’s Project Facilitate. The oncologist. 2021;26(10):e1880-e1882. doi:10.1002/ onco.13910 17. Kang S, Chang S, Ross JS, Miller JE. Implementation of 21st Century Cures Act Expanded Access Policies Requirements. Clin Pharmacol Ther. Published online September 2021. doi:10.1002/cpt.2401 18. Kearns L, Chapman CR, Moch KI, et al. Gene therapy companies have an ethical obligation to develop expanded access policies. Mol Ther. 2021;29(4):1367-1369. doi:10.1016/j. ymthe.2021.03.008 19. Kimberly LL, Beuttler MM, Shen M, Caplan AL, Bateman-House A. Pre-approval Access Terminology. TherInnovRegulSci.2017;51(4):494500. doi:10.1177/2168479017696267
RkJQdWJsaXNoZXIy MTk4NDMw